The issued patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is vital to several essential biological processes, such as cell growth, survival, motility, and metabolism. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Semafore Pharma said that SF1126 product is the only PI3K/mTOR inhibitor prodrug currently in development by the company.
SF1126 product candidate is designed to overcome these concerns by accumulating preferentially in tumor tissue in an attempt to maximise efficacy and minimise toxicity.
Semafore Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases.